Spotlight on once-monthly long-acting injectable aripiprazole and its potential as maintenance treatment for bipolar I disorder in adult patients

References

• MerikangasKRJinRHeJPPrevalence and correlates of bipolar spectrum disorder in the world mental health survey initiativeArch Gen Psychiatry201168324125121383262
   PubMed Web of Science ®Google Scholar
• FerriFRausVBipolar DisorderFerri’s Clinical Advisor 2018Philadelphia, USAElsevier2018190191
   Google Scholar
• VelliganDILamYWGlahnDCDefining and assessing adherence to oral antipsychotics: a review of the literatureSchizophr Bull200632472474216707778
   PubMed Web of Science ®Google Scholar
• MitchellAJSelmesTWhy don’t patients take their medicine? Reasons and solutions in psychiatryAdv Psychiatr Treat2007135336346
   Google Scholar
• ColomFVietaETacchiMJSanchez-MorenoJScottJIdentifying and improving non-adherence in bipolar disordersBipolar Disord20057Suppl 5243116225557
   PubMed Web of Science ®Google Scholar
• HongJReedCNovickDHaroJMAguadoJClinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) StudyPsychiatry Res2011190111011421571375
   PubMed Web of Science ®Google Scholar
• SajatovicMValensteinMBlowFCGanoczyDIgnacioRVTreatment adherence with antipsychotic medications in bipolar disorderBipolar Disord20068323224116696824
   PubMed Web of Science ®Google Scholar
• NovickDMontgomeryWTreuerTAguadoJKraemerSHaroJMRelationship of insight with medication adherence and the impact on outcomes in patients with schizophrenia and bipolar disorder: results from a 1-year European outpatient observational studyBMC Psychiatry201515118926239486
   PubMed Web of Science ®Google Scholar
• RascatiKLRichardsKMOttCAAdherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorderPsychiatr Serv20116291032104021885581
   PubMed Web of Science ®Google Scholar
• HeslinKCElixhauserASteinerCAHospitalizations involving mental and substance use disorders among adults, 2012: Statistical Brief #191HCUP Stat Br2015
   Google Scholar
• KleinmanLLowinAFloodEGandhiGEdgellERevickiDCosts of bipolar disorderPharmacoeconomics200321960162212807364
   PubMed Web of Science ®Google Scholar
• BegleyCEAnnegersJFSwannACThe lifetime cost of bipolar disorder in the US: an estimate for new cases in 1998Pharmacoeconomics2001195 Pt 148349511465308
   PubMed Web of Science ®Google Scholar
• PerlisRHOstacherMJLithium and Its Role in PsychiatrySternTSFavaMWilensTERosenbaumJFMassachusetts General Hospital Comprehensive Clinical Psychiatry2nd edChinaElsevier, Inc201647525531
   Google Scholar
• GeddesJRBurgessSHawtonKJamisonKGoodwinGMLong-term lithium therapy for bipolar disorder: systematic review and meta-analysis of randomized controlled trialsAm J Psychiatry2004161221722214754766
   PubMed Web of Science ®Google Scholar
• Bristol Meyers Squibb, Otsuka Holdings2002Bristol Meyers Squibb, Otsuka Holdings (2002) Abilify™ (Aripiprazole) Approved By U.S. Food And Drug Administration For Treatment Of Schizophrenia. [online press release] Available from: http://www.evaluategroup.com/Universal/View.aspx?type=Story&id=34150Accessed December 3, 2017
   Google Scholar
• Abilify^® (Aripiprazole) [Prescribing Information]Rockville, MDOtsuka America Pharmaceutical, Inc
   Google Scholar
• Texas Department of State Health Services: Aripiprazole for Extended Release Injectable Suspension [Formulary Monograph]2013
   Google Scholar
• Abilify^® (Aripiprazole) [Package Insert]Rockville, MDOtsuka America Pharmaceutical, Inc
   Google Scholar
• WeckerLWattsSFaingoldCDunawayGCrespoLBrody’s Human Pharmacology-E-BookPhiladelphia, USAMosby Inc2010
   Google Scholar
• DaviesMAShefflerDJRothBLAripiprazole: a novel atypical antipsychotic drug with a uniquely robust pharmacologyCNS Drug Rev2006104317336
   Google Scholar
• Di SciascioGRivaMAripiprazole: from pharmacological profile to clinical useNeuropsychiatr Dis Treat2015112635264726508859
   PubMed Web of Science ®Google Scholar
• LeggioGMSalomoneSBucoloCDopamine D3 receptor as a new pharmacological target for the treatment of depressionEur J Pharmacol20137191–3253323872400
   PubMed Web of Science ®Google Scholar
• PichEMColloGPharmacological targeting of dopamine D3 receptors: possible clinical applications of selective drugsEur Neuropsychopharmacol20152591437144726298833
   PubMed Web of Science ®Google Scholar
• PappMGrucaPLason-TyburkiewiczMAdhamNKissBGyertyánIAttenuation of anhedonia by cariprazine in the chronic mild stress model of depressionBehav Pharmacol2014255–656757425083572
   PubMed Web of Science ®Google Scholar
• JordanSKoprivicaVChenRTottoriKKikuchiTAltarCAThe antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptorEur J Pharmacol2002441313714012063084
   PubMed Web of Science ®Google Scholar
• MaharIBambicoFRMechawarNNobregaJNStress, serotonin, and hippocampal neurogenesis in relation to depression and antidepressant effectsNeurosci Biobehav Rev20143817319224300695
   PubMed Web of Science ®Google Scholar
• NaumenkoVSPopovaNKLacivitaELeopoldoMPonimaskinEGInterplay between serotonin 5-HT1A and 5-HT7 receptors in depressive disordersCNS Neurosci Ther201420758259024935787
   PubMed Web of Science ®Google Scholar
• KusumiIBokuSTakahashiYPsychopharmacology of atypical antipsychotic drugs: from the receptor binding profile to neuroprotection and neurogenesisPsychiatry Clin Neurosci201569524325825296946
   PubMed Web of Science ®Google Scholar
• BlierPWardNMIs there a role for 5-HT1A agonists in the treatment of depression?Biol Psychiatry200353319320312559651
   PubMed Web of Science ®Google Scholar
• Mnie-FilaliOLambas-SenasLScarnaHHaddjeriNTherapeutic potential of 5-HT7 receptors in mood disordersCurr Drug Targets200910111109111719702552
   PubMed Web of Science ®Google Scholar
• HedlundPBSutcliffeJGFunctional, molecular and pharmacological advances in 5-HT 7 receptor researchTrends Pharmacol Sci200425948148615559250
   PubMed Web of Science ®Google Scholar
• BickerdikeMJ5-HT2C receptor agonists as potential drugs for the treatment of obesityCurr Top Med Chem20033888589712678838
   PubMed Web of Science ®Google Scholar
• NguyenCTRosenJABotaRGAripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus lowPrim Care Companion CNS Disord2012145 pii: PCC. 12m01386
   Google Scholar
• MarcusRNMcQuadeRDCarsonWHThe efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorderJ Clin Psychopharmacol200828215616518344725
   PubMed Web of Science ®Google Scholar
• GopalakrishnaGAggarwalALaurielloJLong-acting injectable aripiprazole: how might it fit in our tool box?Clin Schizophr Relat Psychoses201372879223644169
   PubMedGoogle Scholar
• MeyerJMUnderstanding depot antipsychotics: an illustrated guide to kineticsCNS Spectr201318Suppl 1586724345710
   PubMed Web of Science ®Google Scholar
• MallikaarjunSKaneJMBricmontPPharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose studySchizophr Res2013150128128823890595
   PubMed Web of Science ®Google Scholar
• JohnstoneECCompanion to Psychiatric Studies8th edChinaChurchill Livingstone2010
   Google Scholar
• TaylorDPsychopharmacology and adverse effects of antipsychotic long-acting injections: a reviewBr J Psychiatry Suppl200952S13S1919880912
   PubMedGoogle Scholar
• GoodnickPJJerryJMAripiprazole: profile on efficacy and safetyExpert Opin Pharmacother20023121773178112472374
   PubMedGoogle Scholar
• Abilify Maintena^® (Aripiprazole) [Prescribing Information]Rockville, MDOtsuka America Pharmaceutical, Inc2017
   Google Scholar
• SachsGSanchezRMarcusRAripiprazole Study GroupAripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled studyJ Psychopharmacol200620453654616401666
   PubMed Web of Science ®Google Scholar
• FountoulakisKNVietaESchmidtFAripiprazole monotherapy in the treatment of bipolar disorder: a meta-analysisJ Affect Disord2011133336137021040979
   PubMed Web of Science ®Google Scholar
• MuzinaDJMomahCEudiconeJMAripiprazole monotherapy in patients with rapid-cycling bipolar I disorder: an analysis from a long-term, double-blind, placebo-controlled studyInt J Clin Pract200862567968718373615
   PubMed Web of Science ®Google Scholar
• SuppesTEudiconeJMcQuadeRPikalovA3rdCarlsonBEfficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorderJ Affect Disord20081071–314515417904226
   PubMed Web of Science ®Google Scholar
• ThaseMEJonasAKhanAAripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studiesJ Clin Psychopharmacol2008281132018204335
   PubMed Web of Science ®Google Scholar
• KeckPEJrCalabreseJRMcIntyreRSAripiprazole Study GroupAripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placeboJ Clin Psychiatry200768101480149117960961
   PubMed Web of Science ®Google Scholar
• KaneJMSanchezRPerryPPAripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled studyJ Clin Psychiatry201273561762422697189
   PubMed Web of Science ®Google Scholar
• FleischhackerWWBakerRAEramoAEffects of aripiprazole once-monthly on domains of personal and social performance: results from 2 multicenter, randomized, double-blind studiesSchizophr Res20141592–341542025281992
   PubMed Web of Science ®Google Scholar
• CalabreseJRSanchezRJinNEfficacy and safety of aripiprazole once-monthly in the maintenance treatment of bipolar I disorder: a double-blind, placebo-controlled, 52-week randomized withdrawal studyJ Clin Psychiatry201778332433128146613
   PubMed Web of Science ®Google Scholar
• GhaemiSNHsuDJThaseMEPharmacological treatment patterns at study entry for the first 500 STEP-BD participantsPsychiatr Serv200657566066516675760
   PubMed Web of Science ®Google Scholar
• JuddLLAkiskalHSSchettlerPJThe long-term natural history of the weekly symptomatic status of bipolar I disorderArch Gen Psychiatry200259653053712044195
   PubMed Web of Science ®Google Scholar